October 11, 2019
Kangpu Biopharmaceuticals doses first humans with KPG-818 for treating SLE and hematological malignancies
Kangpu Biopharmaceuticals has completed a first-in-human phase I single ascending dose (SAD) clinical study in the United States, testing KPG-818 for the treatment of SLE and hematological malignancies.